Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Rhea-AI Summary

Sensei Biotherapeutics, Inc. (SNSE) will participate in Canaccord Genuity's Horizons in Oncology Virtual Conference to discuss KRAS and VISTA targeting in cancer therapy. Dr. Shiraj Sen will represent the company and share insights on the Phase 1/2 clinical trial for SNS-101.

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15^th at 2:00 p.m. ET.

The panel will feature Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas. Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101.

About Sensei Biotherapeutics 
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact: 
Michael Biega 
Senior Director, Investor Relations
Sensei Biotherapeutics 
mbiega@senseibio.com

Media Contact: 
Joyce Allaire 
LifeSci Advisors 
Jallaire@lifesciadvisors.com 

FAQ

What event will Sensei Biotherapeutics (SNSE) participate in?

Sensei Biotherapeutics (SNSE) will participate in Canaccord Genuity's Horizons in Oncology Virtual Conference.

What will be discussed during the panel?

The panel will focus on 'KRAS and VISTA - Better Approaches for Key Targets' in cancer therapy.

Who will represent Sensei Biotherapeutics (SNSE) at the conference?

Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas, will represent Sensei Biotherapeutics (SNSE) at the conference.

What clinical trial will be discussed during the panel?

Dr. Sen will share insights on the ongoing Phase 1/2 clinical trial for SNS-101.